LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Rhythm Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

101.36 1.73

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

98.76

Massimo

101.36

Metriche Chiave

By Trading Economics

Entrata

2.9M

-47M

Vendite

16M

49M

Margine di Profitto

-96.144

Dipendenti

283

EBITDA

6.9M

-40M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+12.34% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

896M

6.9B

Apertura precedente

99.63

Chiusura precedente

101.36

Notizie sul Sentiment di mercato

By Acuity

38%

62%

117 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 set 2025, 23:37 UTC

Azioni calde

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 set 2025, 20:41 UTC

Utili

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 set 2025, 20:30 UTC

Utili

GameStop 2Q Sales, Profit Rise

9 set 2025, 23:19 UTC

Discorsi di Mercato

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 set 2025, 21:35 UTC

Utili

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 21:32 UTC

Utili

Oracle's Backlog Swells With Big Customer Deals -- Update

9 set 2025, 21:02 UTC

Acquisizioni, Fusioni, Takeovers

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 set 2025, 20:33 UTC

Utili

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 set 2025, 20:26 UTC

Utili

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 20:23 UTC

Utili

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 set 2025, 20:12 UTC

Utili

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 set 2025, 20:10 UTC

Utili

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 set 2025, 20:10 UTC

Utili

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 set 2025, 20:09 UTC

Utili

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 set 2025, 20:09 UTC

Utili

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 set 2025, 20:08 UTC

Utili

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 set 2025, 20:08 UTC

Utili

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 set 2025, 20:08 UTC

Utili

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 set 2025, 20:08 UTC

Utili

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 set 2025, 20:07 UTC

Utili

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 set 2025, 20:06 UTC

Utili

Oracle 1Q Software Revenue $5.72B >ORCL

9 set 2025, 20:06 UTC

Utili

Synopsys 3Q Adj EPS $3.39 >SNPS

9 set 2025, 20:06 UTC

Utili

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Rev $14.93B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q EPS $1.01 >ORCL

9 set 2025, 20:05 UTC

Utili

Synopsys 3Q EPS $1.50 >SNPS

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Services Revenue $1.35B >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Adj EPS $1.47 >ORCL

9 set 2025, 20:05 UTC

Utili

Oracle 1Q Hardware Revenue $670M >ORCL

Confronto tra pari

Modifica del prezzo

Rhythm Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

12.34% in crescita

Previsioni per 12 mesi

Media 112.08 USD  12.34%

Alto 135 USD

Basso 95 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

13

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

60 / 65.58Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

117 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat